When Johnson & Johnson reported its second-quarter earnings in July, it said its sales guidance for 2016 continued to assume no biosimilar entrants against its blockbuster rheumatoid arthritis and Crohn's disease drug Remicade (infliximab), even in the face of the FDA's April 5 approval of Pfizer Inc.'s and Celltrion Inc.'s Inflectra (infliximab-dyyb).
But a Massachusetts judge's Aug. 17 ruling declaring J&J's '471 patent on Remicade invalid likely has the company and its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?